NextCureNXTC
Market Cap: $38.6M
About: NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases, and NC181, for Alzheimer's disease.
Employees: 82
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
78% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 9
6.87% more ownership
Funds ownership: 59.31% [Q1] → 66.18% (+6.87%) [Q2]
4% more funds holding
Funds holding: 47 [Q1] → 49 (+2) [Q2]
0% more call options, than puts
Call options by funds: $2K | Put options by funds: $2K
20% less capital invested
Capital invested by funds: $36.9M [Q1] → $29.4M (-$7.47M) [Q2]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Needham Gil Blum 48% 1-year accuracy 74 / 153 met price target | 190%upside $4 | Buy Reiterated | 2 Aug 2024 |